null

SPARCL1 Polyclonal Antibody (CAB20768)

SKU:
CAB20768
Product Type:
Antibody
Antibody Type:
Secondary Antibody
Host Species:
Goat
Isotype:
AMCA conjugated IgG
  • Western blot analysis of extracts of Rat brain, using SPARCL1 antibody at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 90s.
  • Western blot analysis of extracts of Mouse brain, using SPARCL1 antibody at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 90s.
€139 - €419
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

SPARCL1 Polyclonal Antibody (CAB20768)

The SPARCL1 Polyclonal Antibody (CAB20768) is a valuable tool for researchers studying SPARCL1, a protein associated with cell adhesion, tissue remodeling, and tumor suppression. This antibody, produced in rabbits, shows high specificity and sensitivity in detecting SPARCL1 in human samples using Western blot techniques. By binding to the SPARCL1 protein, researchers can analyze its expression in various cell types, aiding in the investigation of its role in cancer progression and metastasis.SPARCL1, also known as secreted protein acidic and rich in cysteine-like 1, is a key player in modulating cell-cell interactions and extracellular matrix remodeling, impacting processes such as cell migration and invasion.

Its tumor-suppressive properties have garnered interest in understanding its mechanisms of action in cancer development and therapy. With its involvement in regulating tumor microenvironment and metastasis, targeting SPARCL1 may offer new opportunities for therapeutic interventions in cancer treatment strategies.Overall, the SPARCL1 Polyclonal Antibody is a reliable tool for researchers interested in unraveling the functions of SPARCL1 in cancer biology, with potential applications in biomarker discovery and drug development efforts aimed at combating cancer progression and metastasis.